Yu Lu

This paper evaluates a three-drug regimen combining TBI-166, bedaquiline, and pyrazinamide against Mycobacterium tuberculosis, showing synergistic effects and metabolic disruption.

This study develops and evaluates PROTAC degraders targeting 11β-HSD1, showing improved glucose tolerance and insulin secretion in a T2DM mouse model.

This study compares the biodistribution of contezolid and linezolid in mice and human patients infected with Mycobacterium abscessus, showing similar tissue levels but different site-specific penetration.

The paper identifies mutations conferring resistance to Macozinone in Mycobacterium tuberculosis through in vitro selection and whole genome sequencing.